TABLE 4

Assessment of accuracy and precision of CL_{int, ML}, CL_met, and CL_uptake parameters for the prediction of in vivo clearance

Data were scaled using standard physiologic scaling factors of 200 mg protein/g liver and 40 g liver/kg bodyweight. For in vivo references see Supplemental Table 2.

Drug						Predicted/Observed
Drug	CL_{int, ML}	CL_met	CL_uptake	CL_{int, in vivo}		CL_{int, ML}	CL_met	CL_uptake
	ml/min per kilogram
Atorvastatin	960 ± 151	272 ± 77	1664 ± 274	1593		0.60	0.17	1.04
Cerivastatin	377 ± 111	38 ± 22	1333 ± 542	1517		0.25	0.03	0.88
Clarithromycin	129 ± 28	70 ± 3.7	371 ± 76	121		1.07	0.58	3.07
Erythromycin	129 ± 54	100 ± 32	387 ± 69	115.5		1.12	0.87	3.35
Indinavir	643 ± 140	420 ± 78	1145 ± 330	50		12.9	8.41	22.94
Midazolam	1851 ± 536	1887 ± 144^{^a}	—	1331		1.39	1.42	—
Pitavastatin	260 ± 10	54 ± 8.7	1201 ± 451	1165		0.22	0.05	1.03
Repaglinide	353 ± 90	206 ± 85	767 ± 152	496		0.71	0.42	1.55
Rosuvastatin	52 ± 42	19 ± 4.0	1658 ± 514	1412		0.04	0.01	1.17
Saquinavir	895 ± 221	1110 ± 327	9282 ± 7351	911		0.98	1.22	10.19
Tolbutamide	6.8 ± 3.1	15 ± 4.4^{^a}	—	7.4		0.92	1.96	—
Valsartan	47 ± 26	17 ± 5.1	171 ± 26	1554		0.03	0.01	0.11
					GMFE	3.13	6.41	2.94
					RMSE	779	915	2771

↵^a Data calculated from conventional depletion assay using eq. 1.